European Union

Published: 18 January 2024
Adopted: 29 November 2023

Wiley Online Library

Full article: Read online at EFSA Journal
Full article (online viewer)

Meta data

EFSA Journal 2024;22(1):8483
DOI https://doi.org/10.2903/j.efsa.2024.8483

Abstract

Genetically modified maize DP23211 was developed to confer control of certain coleopteran pests and tolerance to glufosinate‐containing herbicide. These properties were achieved by introducing the pmi, mo‐pat, ipd072Aa and DvSSJ1 expression cassettes. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize DP23211 and its conventional counterpart needs further assessment, except for those in levels of histidine, phenylalanine, magnesium, phosphorus and folic acid in grain, which do not raise safety and nutritional concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the IPD072Aa, PAT and PMI proteins and the DvSSJ1 dsRNA and derived siRNAs newly expressed in maize DP23211, and finds no evidence that the genetic modification impacts the overall safety of maize DP23211. In the context of this application, the consumption of food and feed from maize DP23211 does not represent a nutritional concern in humans and animals. Therefore, no post‐market monitoring of food/feed is considered necessary. In the case of accidental release of viable maize DP23211 grains into the environment, this would not raise environmental safety concerns. The post‐market environmental monitoring plan and reporting intervals are in line with the intended uses of maize DP23211. The GMO Panel concludes that maize DP23211 is as safe as its conventional counterpart and the tested non‐GM reference varieties with respect to potential effects on human and animal health and the environment.

Website: http://www.efsa.europa.eu

Published: January 18, 2024